文献速递肿瘤 PET/CT神经核医学

「68Ga」Ga-DOTATATE与「68Ga」Ga-NODAGA-LM3 PET/CT头对头比较

Head-to-Head Comparison of [68Ga]Ga-DOTATATE PET/CT and [68Ga]Ga-NODAGA-LM3 PET/CT.
PubMed 文献 · J Nucl Med · 2026-04-01

结果显示「68Ga」Ga-NODAGA-LM3对肝转移检出更多且TBR更高(P=0.006),两示踪剂生理分布模式不同。

要点

  • 「68Ga」Ga-NODAGA-LM3检出肝转移显著多于「68Ga」Ga-DOTATATE(P<0.05)。
  • 肝转移TBR在「68Ga」Ga-NODAGA-LM3显著更高(P=0.006),SUVmax无显著差异。
  • 两示踪剂在正常器官生理分布模式不同,其他区域病灶检出无显著差异。

核心结论

  • 「68Ga」Ga-NODAGA-LM3较「68Ga」Ga-DOTATATE具有更高的TBR和更优的肝转移检出。
  • 两示踪剂在其他区域病灶检出无显著差异,但生理分布模式不同。

研究设计与样本

  • 所有患者在3天内均接受「68Ga」Ga-DOTATATE与「68Ga」Ga-NODAGA-LM3两种PET/CT显像。
  • 对生理摄取区计算SUVmax与SUVmean,对病灶测定SUVmax与TBR,配对数据采用配对样本t检验或Wilcoxon符号秩检验,P<0.05为有统计学意义。

主要发现

  • 患者中位年龄62岁(范围27-90岁),女性占63.4%。
  • 「68Ga」Ga-DOTATATE在肝、脾、胰、空肠的生理活性显著更高。
  • 「68Ga」Ga-NODAGA-LM3在腮腺、纵隔血池、肺、乳腺、肾、子宫的摄取显著更高。
  • 基于病灶分析,「68Ga」Ga-NODAGA-LM3检出肝转移显著多于「68Ga」Ga-DOTATATE(P<0.05),其他区域无显著差异。
  • 肝转移TBR在「68Ga」Ga-NODAGA-LM3显著更高(P=0.006),但两示踪剂间SUVmax无显著差异。

临床怎么用

  • 对于疑似或已知肝转移的神经内分泌肿瘤等患者,可优先考虑「68Ga」Ga-NODAGA-LM3 PET/CT以提高肝转移检出。
  • 阅片时需注意两示踪剂生理分布差异,避免将「68Ga」Ga-NODAGA-LM3在腮腺、肾、子宫等的高摄取误判为异常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study compared the physiologic distribution of [68Ga]Ga-DOTATATE and [68Ga]Ga-NODAGA-LM3 PET/CT, assessed SUV and tumor-to-background ratio (TBR) measurements in primary and metastatic lesions, and evaluated lesion detection performance. Methods: Forty-one adult patients with well-differentiated (G1-G3) gastroenteropancreatic or lung neuroendocrine neoplasms, pheochromocytoma, medullary thyroid carcinoma, and well-differentiated thyroid carcinoma were included in this study. All patients underwent PET/CT imaging with both [68Ga]Ga-DOTATATE and [68Ga]Ga-NODAGA-LM3 within a 3-d interval. SUVmax and SUVmean were calculated for physiologic uptake regions, and SUVmax and TBR were determined for lesions. Paired data were analyzed using the paired-samples t test or Wilcoxon signed-rank test, with a P of less than 0.05 considered statistically significant. Results: The median patient age was 62 y (range, 27-90 y), and 63.4% were women. Analysis of uptake in normal organs revealed that [68Ga]Ga-DOTATATE PET/CT demonstrated significantly higher physiologic activity in the liver, spleen, pancreas, and jejunum, whereas [68Ga]Ga-NODAGA-LM3 showed significantly higher uptake in the parotid glands, mediastinal blood pool, lungs, breasts, kidneys, and uterus. Lesion-based analysis found that [68Ga]Ga-NODAGA-LM3 detected significantly more liver metastases than did [68Ga]Ga-DOTATATE (P < 0.05), with no significant differences observed in other regions. The TBR of liver metastases was significantly higher with [68Ga]Ga-NODAGA-LM3 (P = 0.006), although the SUVmax did not significantly differ between radiotracers. Conclusion: [68Ga]Ga-NODAGA-LM3 demonstrates a higher TBR and superior detection of liver metastases compared with [68Ga]Ga-DOTATATE. Although no significant differences were found in other regions, the 2 radiotracers exhibit distinct physiologic distribution patterns.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Can C, Kömek H, Güzel Y, et al. Head-to-Head Comparison of [68Ga]Ga-DOTATATE PET/CT and [68Ga]Ga-NODAGA-LM3 PET/CT. J Nucl Med. 2026. PMID: 41545070. doi:10.2967/jnumed.125.271074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。